← Back to all signals
RESEARCH PAPER ANALYSIS

Identification and clinical validation of autophagy-related genes as potential biomarkers of Parkinson's disease and their correlation with immune infiltration.

Using public transcriptomic data and machine learning, the authors derived a four-gene autophagy-related blood signature (PRKD1, CAMP, MCOLN3, ATG9B) that discriminates Parkinson's patients from controls (model AUC 0.845) and correlates with altered immune-cell infiltration, with RT-qPCR and plasma…

PMID41926904
JournalClinical neurology and neurosurgery
Publication Date2026-03-31
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Using public transcriptomic data and machine learning, the authors derived a four-gene autophagy-related blood signature (PRKD1, CAMP, MCOLN3, ATG9B) that discriminates Parkinson's patients from controls (model AUC 0.845) and correlates with altered immune-cell infiltration, with RT-qPCR and plasma…

WHY IT MATTERS

Research significance

Provides a clinically accessible autophagy–immune linked biomarker panel with modest diagnostic performance and nominates mechanistically relevant genes (autophagy/lysosomal and immune-related) for follow-up as potential therapeutic targets or stratification tools, though prospective validation and…

ABSTRACT

Source abstract

BACKGROUND: Parkinson's disease (PD) is the second most common progressive neurodegenerative disease that severely affects the quality of life and there is an urgent need to explore unique and effective diagnostic markers. The present study aimed to develop and validate a multigene combination model for the diagnosis of PD based on autophagy-related genes (ARGs) and to discover their correlation with immune infiltrating cells. METHODS: We downloaded the dataset GSE49126 from the database and retrieved ARGs from three databases. Differentially expressed ARGs were filtered by three machine algorithms and applied to construct diagnostic models. We then analyzed the differences in immune microenvironment between PD and controls utilizing ImmuCellAI and CIBERSORT, followed by investigating the correlation between markers and immune cells to better understand the molecular interactions mechanisms. Finally, the expression of key ARGs was validated in Peripheral blood mononuclear cells (PBMC) and plasma using RT-qPCR and ELISA respectively. RESULTS: A total of 28 differentially expressed ARGs were identified, and a four-gene diagnostic model (PRKD1, CAMP, MCOLN3, and ATG9B) was established, demonstrating favorable diagnostic performance (AUC = 0.845, 95% CI: 0.736-0.954). Immune infiltration analysis revealed alterations in the immune microenvironment in PD, and correlation analysis indicated significant associations between model ARGs and immune cell subsets. RT-qPCR validation showed increased expression of PRKD1, CAMP, and ATG9B in PBMCs from patients with PD compared with age- and sex-matched healthy controls (p < 0.05), consistent with transcriptomic findings. In contrast, MCOLN3 expression was decreased in patients with PD. Plasma CAMP protein levels were reduced in PD and demonstrated diagnostic potential (AUC = 0.771, 95% CI: 0.696-0.845). CONCLUSIONS: An ARG-based diagnostic model comprising PRKD1, CAMP, MCOLN3, and ATG9B demonstrated potential diagnostic value for PD and revealed associations between autophagy-related signatures and immune alterations. These findings provide exploratory evidence supporting the involvement of autophagy-immune interactions in PD and warrant further validation in larger prospective cohorts.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic